Functionalized bone marrow organoids for tissue regeneration, their preparation methods and applications

By loading bone marrow mesenchymal stem cells and endothelial cells onto an agarose microwell array and developing them in a conditioned medium using silicate bioceramics, functionalized bone marrow organoids were constructed, solving the problems of insufficient endothelial network maintenance and hematopoietic stem cell regulation, and achieving effective regeneration of bone and cartilage.

CN123107916APending Publication Date: 2026-11-17SHANGHAI INST OF CERAMIC CHEM & TECH CHINESE ACAD OF SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202510634610.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-05-16
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing bone marrow organoids do not maintain the endothelial network well, have insufficient hematopoietic stem cell regulation, and lack platforms for co-culturing with other functional cells, thus affecting tissue regeneration.

Method used

Bone marrow mesenchymal stem cells and endothelial cells were loaded into an agarose microwell array and then developed into functional bone marrow organoids in conditioned medium using silicate bioceramics, thereby optimizing their structural and functional properties.

Benefits of technology

Functionalized bone marrow organoids exhibit excellent endothelial network maintenance, mesenchymal compartment structure features, and regulation of HSCs, significantly promoting bone and cartilage regeneration and providing a repair strategy for bone-related defects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123107916A_ABST
    Figure CN123107916A_ABST
Patent Text Reader

Abstract

This invention belongs to the field of biomaterials and relates to a functionalized bone marrow organoid for tissue regeneration, its preparation method, and its application. The functionalized bone marrow organoid is an organoid with natural bone marrow structure and functional characteristics, formed by the spontaneous aggregation of bone marrow mesenchymal stem cells and endothelial cells loaded onto an agarose microporous array and developed in a conditioned medium containing silicate bioceramics. The functionalized bone marrow organoid designed in this invention exhibits excellent endothelial network maintenance, mesenchymal compartment structural features, and regulatory effects on hematopoietic stem cells. Furthermore, compared with two-dimensionally cultured cells, the functionalized bone marrow organoid can effectively promote osteochondral regeneration. Therefore, this invention provides a new method for regulating important cellular functions and improving tissue regeneration by constructing functionalized organoids based on silicate biomaterials.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biomaterials, specifically relating to functionalized bone marrow organoids for tissue regeneration, their preparation methods, and applications. Background Technology

[0002] Organoids are three-dimensional structures formed from stem cells in vitro. They can mimic the structural and functional characteristics of real tissues or organs, providing an important platform for disease modeling, drug screening, and regenerative medicine. Tissue regeneration refers to the repair or replacement of damaged tissues and the restoration of their function through various means such as biomaterials, stem cells, or growth factors. The pluripotency and self-renewal properties of organoids, as well as enhanced intercellular interactions, make them highly promising for applications in the field of tissue regeneration.

[0003] Bone marrow, a soft tissue located within bones, participates in the functions of the human immune system, blood circulation, and skeletal system. It plays a crucial role in bone repair, providing abundant stem cells, such as mesenchymal stem cells (MSCs), for bone injury repair. Furthermore, bone marrow provides a suitable microenvironment for bone repair, rich in growth factors, nutrients, and signaling molecules, supporting cell survival and functional maintenance. Therefore, the development of bone marrow organoids offers a potential strategy for repairing skeletal system injuries. It is noteworthy that the structure and function of bone marrow organoids still require further optimization based on existing strategies for constructing them. For example, the endothelial network in bone marrow organoids gradually diminishes over time, and its maintenance needs further improvement. In addition, the regulatory effect on hematopoietic stem cells (HSCs) holds promise for restoring bone marrow function, which is crucial for the regeneration of damaged tissues. Moreover, the co-culture of organoids with other functional cells can not only be used to study the functional properties of organoids but also provide an effective platform for simulating the interactions between tissues and other cells in vitro. Summary of the Invention

[0004] To address the problems existing in the prior art, the present invention aims to provide a functionalized bone marrow organoid, its preparation method, and its applications. The functionalized bone marrow organoids designed in this invention exhibit excellent endothelial network maintenance, mesenchymal compartment structure characteristics, and regulatory effects on hematopoietic stem cells. Furthermore, results from rabbit osteochondral repair models demonstrate that, compared to two-dimensionally cultured cells, functionalized bone marrow organoids can effectively promote osteochondral regeneration. Therefore, the functionalized organoids constructed based on silicate biomaterials in this invention provide a novel method for regulating important cellular functions and improving tissue regeneration.

[0005] In a first aspect, the present invention provides a functionalized bone marrow organoid. The functionalized bone marrow organoid is an organoid possessing the structure and functional characteristics of natural bone marrow, formed by the spontaneous aggregation of mesenchymal stem cells and endothelial cells loaded onto an agarose microporous array, and developed in a conditioned medium containing silicate bioceramics.

[0006] Preferably, the endothelial cells are human umbilical vein endothelial cells.

[0007] Preferably, the initial loading ratio of bone marrow mesenchymal stem cells to endothelial cells is 1:1 to 3:1.

[0008] Preferably, the total number of bone marrow mesenchymal stem cells and endothelial cells seeded in each well of the agarose microwell array is 400 to 1000.

[0009] Preferably, the silicate bioceramic is calcium silicate and / or magnesium silicate.

[0010] Preferably, the mass concentration of silicate bioceramics in the conditioned medium is not higher than 200 μg / mL, and more preferably 50 to 100 μg / mL.

[0011] Preferably, the agarose mass fraction of the agarose micropore array is 1.5% to 3%.

[0012] Secondly, the present invention provides a method for preparing the aforementioned functionalized bone marrow organoids. The method includes: seeding bone marrow mesenchymal stem cells and endothelial cells into an agarose microwell array, culturing them until they spontaneously aggregate to form mesenchymal spheres; dispersing bioceramics into a complete organoid culture medium to obtain a conditioned medium; subsequently changing the culture environment and the medium to a conditioned medium, and continuing the culture to construct the functionalized bone marrow organoids.

[0013] Thirdly, the present invention provides the application of the aforementioned functionalized bone marrow organoids in the preparation of tissue regeneration materials.

[0014] Beneficial effects

[0015] The functionalized bone marrow organoids provided by this invention exhibit excellent endothelial network maintenance, mesenchymal compartment structure characteristics, and regulatory effects on HSCs. The constructed organoid-cell co-culture model demonstrates that, compared to two-dimensional cells, the organoids possess ideal in vitro bioactivity. Results in rabbit osteochondral repair show that functionalized bone marrow organoids can effectively promote bone and cartilage regeneration, providing a strong validation model for the use of functionalized bone marrow organoids in the repair of bone-related defects. Therefore, functionalized bone marrow organoids based on silicate bioactive materials offer a novel strategy for regulating important cellular functions and improving tissue regeneration, with broad application prospects. Attached Figure Description

[0016] Figure 1 The crystal phase and microstructure of calcium silicate (CS) were characterized. (a) XRD pattern of the prepared calcium silicate nanowires. (b) SEM image of the prepared calcium silicate nanowires. (c) TEM image of the prepared calcium silicate nanowires. The results show that the prepared calcium silicate has a nanowire morphology and good dispersion.

[0017] Figure 2 The crystal phase and microstructure of magnesium silicate (MS) were characterized. (a) XRD pattern of the prepared magnesium silicate nanospheres. (b) SEM image of the prepared magnesium silicate nanospheres. (c) TEM image of the prepared magnesium silicate nanospheres. The results show that the prepared magnesium silicate nanospheres are hollow nanospheres with a diameter of approximately 400 nm.

[0018] Figure 3 Representative bright-field images of bone marrow organoids formed from different proportions of bone marrow mesenchymal stem cells (MSCs) and endothelial cells (ECs) at different time points (days 1, 3, 7, 10, and 14). Scale bar: 200 μm.

[0019] Figure 4 Developmental assessment of bone marrow organoids constructed with different proportions of bone marrow mesenchymal stem cells and endothelial cells. (a) ENG and CD31 staining images of bone marrow organoids constructed with different cell proportions at day 7 and day 14. (b) NESTIN staining of three groups of bone marrow organoids (100 / 0, 75 / 25, and 50 / 50) cultured for 7 and 14 days.

[0020] Figure 5 The mean fluorescence intensity of ENG, CD31, and NESTIN in bone marrow organoids constructed from different proportions of bone marrow mesenchymal stem cells and endothelial cells was statistically analyzed. The results showed that the 75 / 25 group exhibited a relatively superior endothelial network; in addition, the expression of ENG, CD31, and NESTIN in all groups decreased with prolonged culture time.

[0021] Figure 6 Calcium silicate was used to promote the development of bone marrow organoids. (a) Images of ENG and CD31 staining in bone marrow organoids cultured in conditioned media containing different concentrations of calcium silicate. (b) Statistical analysis of the average fluorescence intensity of ENG and CD31 expression in different bone marrow organoids. The results showed that an appropriate concentration of calcium silicate could promote the expression of ENG and CD31 in bone marrow organoids and maintain this effect for a relatively long time.

[0022] Figure 7(a) NESTIN staining images of bone marrow organoids constructed with different concentrations of calcium silicate; (b) mean fluorescence intensity of NESTIN expression in bone marrow organoids formed under different calcium silicate treatments. The results show that an appropriate concentration of calcium silicate S can promote NESTIN expression in bone marrow organoids.

[0023] Figure 8 Magnesium silicate was used for the development of bone marrow organoids. (a) Images of ENG and CD31 staining in bone marrow organoids cultured in conditioned media containing different concentrations of magnesium silicate. (b) Statistical analysis of the average fluorescence intensity of ENG and CD31 expression in different bone marrow organoids. The results showed that an appropriate concentration of magnesium silicate could promote the expression of ENG and CD31 in bone marrow organoids and maintain this effect for a relatively long time.

[0024] Figure 9 (a) NESTIN staining images of bone marrow organoids constructed with different concentrations of magnesium silicate; (b) mean fluorescence intensity of NESTIN expression in bone marrow organoids formed under different magnesium silicate conditions. The results show that an appropriate concentration of magnesium silicate can promote NESTIN expression in bone marrow organoids.

[0025] Figure 10 Histological staining results of bone marrow organoids constructed under the same concentrations of calcium silicate or magnesium silicate after 7 days (a) and 14 days (b) of culture. Organoid structures are represented by hematoxylin and eosin (H&E) staining. Alcian blue (AB) staining marks acidic polysaccharides and chondrogenic differentiation. Oil Red O staining shows adipogenic differentiation. Periodic acid-Schiff (PAS) staining is used for polysaccharide staining. Sirius red (SR) staining is used for collagen staining. Scale bar: 100 μm. (c) RUNX2 staining images of bone marrow organoids formed under calcium silicate or magnesium silicate after 7 and 14 days of culture. (d) Statistical results of mean fluorescence intensity of RUNX2. Bone marrow organoids cultured in complete medium are designated BMO; organoids formed in conditioned medium containing 50 μg / mL calcium silicate or magnesium silicate are designated BMO / CS and BMO / MSS, respectively. The results showed that bone marrow organoids cultured for 7 and 14 days exhibited the extracellular matrix components of MSCs in natural bone marrow, including glycogen and collagen, as well as self-renewal and differentiation characteristics, allowing partial differentiation into adipocytes, chondrocytes and osteoblasts.

[0026] Figure 11 To investigate the regulatory effects of functionalized bone marrow organoids on hematopoietic stem cells (HSCs). (a) The recruitment effects of different bone marrow organoids on hematopoietic stem cells. (b) Quantitative analysis of CD45 homing for each organoid. +Cell number. (c) Flow cytometry analysis of HSCs labeled with carboxyfluorescein succinimide (CFSE) after 5 days of co-culture with bone marrow organoids and hematopoietic stem cells. (d) Apoptosis test of HSCs after 10 days of co-culture with different bone marrow organoids. The results showed that, compared with single bone marrow organoids, functionalized bone marrow organoids constructed under CS or MS treatment could promote HSC recruitment, division and inhibit apoptosis.

[0027] Figure 12 The release behavior of Ca, Si, and Mg ions in CS and MS bioceramics.

[0028] Figure 13 To illustrate the effects of functionalized bone marrow organoids on chondrocytes. (a) Col 2 and Sox9 staining images of the cell group and organoid group co-cultured with chondrocytes for 5 days. Scale bar: 100 μm. Cell-based groups refer to MSCs and ECs simultaneously cultured in different media and then mixed at the same cell ratio (3:1) and quantity as the bone marrow organoid construction. Cells cultured in complete medium were designated as the Cells group, while cells treated with conditioned medium containing CS and MS powders were designated as Cells / CS and Cells / MSS, respectively. (b) Expression of chondrocyte differentiation-related genes (Aggrecan and Sox9) in different groups. The results showed that organoids were more effective in promoting chondrocyte differentiation compared to the two-dimensional cell mixture.

[0029] Figure 14 To illustrate the effect of functionalized bone marrow organoids on MSCs. (a) Col 1 and Opn staining images of the cell group and organoid group co-cultured with MSCs for 5 days. Scale bar: 100 μm. (b) Expression of osteogenic-related genes (Col 1 and Runx2) in different groups. The results show that bone marrow organoids have better in vitro osteogenic activity compared to two-dimensional cell mixtures.

[0030] Figure 15 To illustrate the in vivo osteochondral repair effect of functionalized bone marrow organoids. (a) Micro-CT images of the cross-section and longitudinal section of newly formed bone (green); (b) Statistical analysis of the ratio of new bone volume (BV) to total defect volume (TV) in different groups based on Micro-CT results. The results showed that the BV / TV ratio of the BMO / MSS group was significantly higher than that of the other four groups. In particular, the newly formed bone volume in the BMO / MSS group was also significantly higher than that in the BMO group, indicating that functionalized bone marrow organoids under MSS treatment have superior in vivo osteogenic activity.

[0031] Figure 16H&E staining images of osteochondral regeneration. Scale bar: 1 mm. Results showed that the Cells group, Cells / MSS group and BMO group still had varying degrees of cartilage defects, while the cartilage layer in the BMO / MSS group grew well. Detailed Implementation

[0032] The present invention will be further described below with reference to the accompanying drawings and the following embodiments. It should be understood that the drawings and the following embodiments are for illustrative purposes only and are not intended to limit the present invention. The following exemplifies the functionalized bone marrow organoids constructed from silicate biomaterials, their preparation methods, and applications.

[0033] The functionalized bone marrow organoids are organoids with the structure and function of natural bone marrow, formed by the spontaneous aggregation of mesenchymal stem cells and endothelial cells loaded onto an agarose microporous array and developed in a conditioned medium containing silicate bioceramics. Specifically, the functionalized bone marrow organoids are formed under the action of silicate biomaterials.

[0034] The construction of the functionalized bone marrow organoids requires the following materials: agarose micropore array, bone marrow mesenchymal stem cells (MSCs), endothelial cells (ECs), and appropriate amounts of calcium silicate (CS) or magnesium silicate (MS).

[0035] Normal melting point agarose typically dissolves in water when heated to above 90°C and forms a good semi-solid gel when the temperature drops to 35-40°C. Low melting point agarose can also be used. Low melting point agarose is chemically modified agarose. Due to its low-temperature gelation characteristics, low melting point agarose is beneficial for constructing agarose microporous array platforms; furthermore, it can reduce stem cell damage and promote organoid formation. For example, low melting point agarose is agarose with hydroxyethyl, methoxy, or other groups introduced into the polysaccharide chain. Low melting point agarose can be purchased commercially. In some embodiments, the melting point of low melting point agarose is no higher than 65°C. As an example, low melting point agarose that gels at around 30°C and melts at approximately 65°C is used.

[0036] The pore size and number of pores in an agarose microporous array are not limited. As an example, the pore size of an agarose microporous array is 200–600 μm, and the number of pores is 100–500.

[0037] Inorganic bioactive materials possess excellent stem cell regulatory effects and offer advantages in promoting organoid growth and development. Among them, the bioactive ions released by calcium silicate and magnesium silicate bioceramics can promote angiogenesis and regulate intercellular interactions. Therefore, under the influence of calcium silicate and magnesium silicate bioceramics, the development of bone marrow organoids is expected to be further optimized, including enhancing the maintenance of vascular networks, promoting the regulation of hematopoietic stem cells (HSCs), and constructing a sound organoid-cell co-culture system, further facilitating the application of bone marrow organoids.

[0038] The sources of calcium silicate and magnesium silicate bioceramics are unrestricted. For example, calcium silicate and magnesium silicate bioceramics can be synthesized via hydrothermal methods.

[0039] The morphology of calcium silicate and magnesium silicate bioceramics is not limited. Calcium silicate is not limited to nanowire morphology. Magnesium silicate is not limited to nanosphere morphology. In some embodiments, calcium silicate is in the form of nanowires with a length of 1–10 μm and a diameter of 10–50 nm. In other embodiments, magnesium silicate is in the form of nanospheres with a diameter of approximately 400 nm.

[0040] The mass concentration of calcium silicate or magnesium silicate in the conditioned medium can be 0–200 μg / mL. As an example, the mass fraction of calcium silicate or magnesium silicate is 50 μg / mL.

[0041] The agarose mass fraction of the agarose microarray can be 1.5–3 wt%. As an example, the mass fraction of the agarose microarray is 2.5 wt%.

[0042] The initial loading ratio of bone marrow mesenchymal stem cells (MSCs) to endothelial cells is 1:1 to 3:1. For example, the preferred seeding ratio of MSCs to endothelial cells is 3:1. The total number of MSCs and endothelial cells seeded in each well of the agarose microwell array is 400 to 1000. Preferably, the total number of MSCs and endothelial cells seeded in each well of the agarose microwell array is 500. For example, the seeding ratio of MSCs and ECs per well is 375 MSCs and 125 ECs.

[0043] The conditioned medium consists of an appropriate concentration of calcium silicate or magnesium silicate, and an organoid complete medium. Any organoid complete medium commonly used in the art can be used. As an example, the components of the organoid complete medium may include: Dulbecco's Modified Eagle Medium / Nutrient Mixture F-12 (DMEM / F12) and human endothelial serum-free medium (SFM) supplemented with 0.1 mM 2-mercaptoethanol, 1 vol% non-essential amino acids, 1 vol% N2, 1 vol% B27 supplement, 1 vol% P / S, 20 ng / mL recombinant human fibroblast growth factor 2 (hFGF-2), recombinant human epidermal growth factor (hEGF), recombinant human platelet-derived growth factor AB (hPDGF-AB), recombinant human oncogene M (hOSM), 40 ng / mL recombinant human insulin-like growth factor 1 (hIGF-1), and 2 vol% chicken embryo extract (CEE). The volume ratio of DMEM / F12 to SFM medium is 1:2.

[0044] The following exemplarily illustrates the method for preparing the functionalized bone marrow organoids of the present invention.

[0045] Agarose microporous array was prepared. An aqueous solution of agarose with a specific mass fraction was prepared and autoclaved. The agarose solution was then poured into a mold with micropores. After cooling, the agarose microporous array was removed. For example, the mold had 217 micropores with a diameter of 400 μm.

[0046] MSCs and ECs were digested with trypsin, centrifuged, and counted. After inoculation of MSCs and ECs for a period of time (e.g., 24 hours), CS or MS was added to the organoid complete culture medium at a specific ratio to prepare different conditioned media. Subsequently, different organoid media were used, and culture continued for a certain period to construct functional bone marrow organoids. The culture time for organoids was 7–14 days, preferably 7 days. Alternatively, the CS or MS dispersion after sonication could be added to the organoid complete culture medium. The key is to control the concentration of CS or MS to meet the requirements.

[0047] In some embodiments of the present invention, MSCs and ECs are mixed and seeded in different ratios onto a low-melting-point agarose microarray, allowing them to spontaneously aggregate and form three-dimensional multicellular constructs. These are then cultured for at least 7 days to form bone marrow organoids. The seeding ratios of MSCs and ECs are 100 / 0, 75 / 25, and 50 / 50, respectively. A 100 / 0 group is seeded with 500 MSCs per well. A 50 / 50 group is seeded with 250 MSCs and 250 ECs per well. A 75 / 25 group is seeded with 375 MSCs and 125 ECs per well.

[0048] In one embodiment of the present invention, the inoculation ratio of MSCs and ECs is consistent with that of the 75 / 25 group. On day 1, conditioned medium containing CS or MS is added to the organoid culture system, and functional bone marrow organoids are constructed by day 7. Bone marrow organoids cultured in complete medium are called BMOs, while organoids formed in conditioned medium containing 50 μg / mL CS or MS are named BMO / CS and BMO / MSS, respectively.

[0049] The following describes the preparation method of functionalized bone marrow organoids using BMO / MSS as an example. A 2.5 wt% low-melting-point agarose aqueous solution was prepared and autoclaved. The low-melting-point agarose solution was then poured into a microporous mold with 217 micropores, each 400 μm in diameter. After cooling, the low-melting-point agarose microporous array was removed. MSCs and ECs were digested with trypsin, centrifuged, and counted. Each well was inoculated with 375 MSCs and 125 ECs (75 / 25 group). 24 h after MSC and EC inoculation, an ultrasound-treated MS nanosphere (MSS) dispersion was added to the organoid complete culture medium at a ratio of 50 μg / mL MSS. The culture was continued in conditioned medium for a certain period to construct functionalized bone marrow organoids.

[0050] The functionalized bone marrow organoids of this invention are primarily used to promote tissue regeneration. This invention provides the use of these functionalized bone marrow organoids in regulating cell behavior and promoting osteochondral repair, particularly in the repair of osteochondral defects.

[0051] In summary, the functionalized bone marrow organoids prepared in this invention show significantly improved development and also demonstrate good regulatory ability on HSCs. The functionalized bone marrow organoids exhibit good in vitro bioactivity, including promoting chondrocyte differentiation and osteogenic differentiation of MSCs in co-culture. In vivo osteochondral repair results show that the functionalized bone marrow organoids can effectively promote the repair of osteochondral defects in rabbits, providing a strong validation model for the use of bone marrow organoids in the repair of skeletal system defects.

[0052] The following examples further illustrate the present invention in detail. It should also be understood that the following examples are only for further explanation of the present invention and should not be construed as limiting the scope of protection of the present invention. Any non-essential improvements and adjustments made by those skilled in the art based on the above description of the present invention are within the scope of protection of the present invention. The specific process parameters, etc., in the following examples are merely examples within a suitable range; that is, those skilled in the art can make appropriate selections within the appropriate range based on the description herein, and are not intended to be limited to the specific values ​​in the examples below.

[0053] Characterization of CS.

[0054] The preparation method of CS is referenced in (A bioactive calcium silicate nanowire-containing hydrogel for organoid formation and functionalization, Mater. Horiz., 2024, 11, 2957-2973). The crystal phase and morphology of the prepared CS were characterized by X-ray diffraction (XRD), scanning electron microscopy (SEM), and transmission electron microscopy (TEM). Its composition is Ca6Si6O. 17 (OH)₂, with a morphology of nanowires, a length of several micrometers, and a diameter of approximately 10–50 nm (see [link]). Figure 1 ).

[0055] Characterization of MS.

[0056] The preparation method of MS is described in the reference (3D multicellular micropatterning biomaterials for hair regeneration and vascularization, Mater. Horiz., 2023, 10, 3773-3784). XRD analysis of the synthesized MS showed that its diffraction pattern corresponded to Mg3Si4O. 10 (OH)₂ (PDF No. 19-0770) also exhibits low crystallinity. Furthermore, the morphology of the MS sample consists of hollow nanospheres with a diameter of approximately 400 nm. (See...) Figure 2 ).

[0057] Example 1

[0058] A 2.5 wt% low-melting-point agarose aqueous solution was prepared and autoclaved. The solution was then poured into a microporous mold with 217 wells (400 μm in diameter). After cooling, the agarose microwell array was removed. MSCs were digested with trypsin, centrifuged, and counted. 500 MSCs were inoculated into each well. 24 hours after inoculation, the MSCs spontaneously aggregated to form mesenchymal spheroids. The culture medium was then replaced with fresh organoid complete medium, and cultured for another 7–14 days. The complete culture medium consisted of DMEM / F12 medium and serum-free human endothelial culture medium (SFM) supplemented with 0.1 mM 2-mercaptoethanol, 1% non-essential amino acids, 1% N2, 1% B27 supplement, 1% P / S, 20 ng / mL recombinant human fibroblast growth factor 2 (hFGF-2), recombinant human epidermal growth factor (hEGF), recombinant human platelet-derived growth factor AB (hPDGF-AB), recombinant human oncogenes M (hOSM), 40 ng / mL recombinant human insulin-like growth factor 1 (hIGF-1), and 2% chicken embryo extract (CEE). The volume ratio of DMEM / F12 to SFM medium was 1:2.

[0059] Example 2

[0060] A 2.5 wt% low-melting-point agarose aqueous solution was prepared and autoclaved. The solution was then poured into a microporous mold with 217 wells (400 μm in diameter). After cooling, the microporous array of low-melting-point agarose was removed. MSCs and ECs were digested with trypsin, centrifuged, and counted. 250 MSCs and 250 ECs were inoculated into each well. 24 hours after inoculation, the medium was replaced with fresh organoid complete culture medium, and cultured for 7–14 days to form bone marrow organoids.

[0061] Example 3

[0062] A 2.5 wt% low-melting-point agarose aqueous solution was prepared and autoclaved. The solution was then poured into a microporous mold with 217 wells (400 μm in diameter). After cooling, the microporous array of low-melting-point agarose was removed. MSCs and ECs were digested with trypsin, centrifuged, and counted. 375 MSCs and 125 ECs were inoculated into each well. 24 hours after inoculation, the culture medium was replaced with fresh organoid culture medium, and cultured for 7–14 days to form bone marrow organoids.

[0063] The developmental effects of the prepared organoids were analyzed, and the results are shown in [reference needed]. Figure 3-5 .

[0064] The differentiation cell types of the mesenchymal compartments of bone marrow organoids were investigated, and the results are shown in [reference needed]. Figure 10 .

[0065] The effects of the prepared bone marrow organoids on the recruitment, division, and apoptosis of HSCs were tested; the results are shown below. Figure 11 .

[0066] The in vitro bioactivity of the prepared bone marrow organoids was investigated, and the results are shown in [reference needed]. Figure 13-14 .

[0067] The study investigated how the prepared bone marrow organoids promoted the repair of osteochondral defects in vivo. The results are shown in [link to study]. Figure 15-16 .

[0068] Example 4

[0069] A 2.5 wt% low-melting-point agarose aqueous solution was prepared and autoclaved. The solution was then poured into a microporous mold with 217 wells (400 μm in diameter). After cooling, the microporous array of low-melting-point agarose was removed. MSCs and ECs were digested with trypsin, centrifuged, and counted. 375 MSCs and 125 ECs were inoculated into each well. 24 hours after inoculation, the medium was replaced with organoid culture medium containing 50 μg / mL, 100 μg / mL, and 200 μg / mL CS, and cultured for 7–14 days to form bone marrow organoids.

[0070] The developmental effects of the prepared organoids were analyzed, and the results are shown in [reference needed]. Figure 6-7 .

[0071] Bone marrow organoids cultured in organoid culture medium containing 50 μg / mL CS were used as the optimal experimental medium for subsequent evaluation.

[0072] The differentiation cell types of the intermediate mesenchymal compartment in bone marrow organoids were investigated, and the results are shown in [reference needed]. Figure 10 .

[0073] The effects of the prepared bone marrow organoids on the recruitment, division, and apoptosis of HSCs were tested; the results are shown below. Figure 11 .

[0074] The in vitro bioactivity of the prepared bone marrow organoids was investigated, and the results are shown in [reference needed]. Figure 13-14 .

[0075] The study investigated how the prepared bone marrow organoids promoted the repair of osteochondral defects in vivo. The results are shown in [link to study]. Figure 15-16 .

[0076] Example 5

[0077] A 2.5 wt% low-melting-point agarose aqueous solution was prepared and autoclaved. The solution was then poured into a microporous mold with 217 wells (400 μm in diameter). After cooling, the microporous array of low-melting-point agarose was removed. MSCs and ECs were digested with trypsin, centrifuged, and counted. 375 MSCs and 125 ECs were inoculated into each well. 24 hours after inoculation, the medium was replaced with organoid culture medium containing 50 μg / mL, 100 μg / mL, and 200 μg / mL MS, and cultured for 7–14 days to form bone marrow organoids.

[0078] The developmental effects of the prepared organoids were analyzed, and the results are shown in [reference needed]. Figure 8-9 .

[0079] Bone marrow organoids cultured in organoid medium containing 50 μg / mL MS were used as the optimal experimental medium for subsequent evaluation.

[0080] The developmental effects of the prepared functional organoids were analyzed, and the results are shown in [reference needed]. Figure 8-9 .

[0081] The differentiated cell types of the intermediate mesenchymal compartments of the prepared bone marrow organoids were investigated, and the results are shown in [reference needed]. Figure 10 .

[0082] The effects of the prepared bone marrow organoids on the recruitment, division, and apoptosis of HSCs were tested; the results are shown below. Figure 11 .

[0083] The in vitro bioactivity of the prepared bone marrow organoids was investigated, and the results are shown in [reference needed]. Figure 13-14 .

[0084] The study investigated how the prepared bone marrow organoids promoted the repair of osteochondral defects in vivo. The results are shown in [link to study]. Figure 15-16 .

[0085] Construction of bone marrow organoids.

[0086] Natural bone marrow contains two main cellular niche components: MSCs and ECs. Therefore, by modulating the ratio and behavior of these two cell types, it is hoped to construct cellular structures similar to natural bone marrow, i.e., bone marrow organoids. Bone marrow organoids were constructed using agarose microwell arrays loaded with microarrays of varying MSC and EC ratios. These two cell types spontaneously aggregated in the low-cell-adhesion agarose microwell array to form mesenchymal spheroids, which then developed into organoids with the structural and functional characteristics of natural bone marrow.

[0087] Examples 1-3 verified the effect of different MSCs and ECs cell ratios. First, optical images of spheres formed at different time points with different cell ratios were captured. Bright-field image results showed that spheres can be generated efficiently and robustly on a microporous array. Figure 3 Furthermore, the spheroid size in the 75 / 25 and 50 / 50 groups decreased over time. Minimal spheroid growth was detected in the 50 / 50 condition due to the increased proportion of ECs. Subsequently, the three types of spheroids cultured for 7 and 14 days were double-stained with mesenchymal markers (Endoglin, ENG) and endothelial markers (CD31). Figure 4 a). Furthermore, NESTIN is an important mesenchymal factor in the bone marrow mesenchymal compartment, involved in the recruitment and angiogenesis of HSCs. NESTIN staining results showed that the presence of ECs could increase NESTIN expression ( Figure 4 (b) In addition, the mean fluorescence intensities of ENG, CD31, and NESTIN were statistically analyzed. ENG expression was higher in the 75 / 25 and 50 / 50 groups than in the 100 / 0 group. On day 7, CD31 expression was highly significant in both the 75 / 25 and 50 / 50 groups, and the endothelial network was clearly visible. The expression was more significant in the 75 / 25 group. However, on day 14, CD31 expression decreased significantly, indicating poor endothelial network maintenance. NESTIN expression was higher in the 75 / 25 and 50 / 50 groups than in the 100 / 0 group. However, the NESTIN network also showed a significant decrease over time (see [link to relevant documentation]). Figure 5 In the subsequent bone marrow organoid construction, a cell ratio of 75 / 25 was selected as the optimal condition for organoid construction.

[0088] Development of functionalized bone marrow organoids under the influence of CS or MS.

[0089] In the above analysis, the stable network structure found in the two-cell constructed spheroids indicates that the constructed three-dimensional mesenchymal spheroids can partially mimic the vascular niche in the natural bone marrow environment, revealing the structural characteristics of bone marrow. The 75 / 25 group showed a relatively superior endothelial network, which plays an important role in the function of organoids. Therefore, in subsequent studies, spheroids with a cell ratio of 75 / 25 were selected as the optimal construction strategy for bone marrow organoids.

[0090] Inorganic bioactive materials hold immense application potential in the field of organoids. Numerous studies have shown that bioactive ions released from silicate materials, such as silicon and magnesium ions, have a positive impact on angiogenesis. Furthermore, silicate materials with different elemental compositions exhibit varying effects in promoting organoid development. Therefore, considering the roles of different silicate material components in maintaining the endothelial network of bone marrow organoids and other potential influences, this study proposes introducing CS and MS into the culture system of bone marrow organoids to promote their development into functional bone marrow organoids.

[0091] First, bone marrow organoid development was stimulated using four different concentrations of CS. The control group consisted of bone marrow organoids obtained from complete organoid culture medium without CS. Images of ENG and CD31 staining, along with corresponding mean fluorescence intensity statistics, showed that CS supplementation further maintained the endothelial network of bone marrow organoids. On day 14, compared to the control group, the 100 μg / mL group showed enhanced ENG expression, indicating a certain promoting effect on organoid development. Overall, a CS concentration of 50 μg / mL was the most effective in maintaining the endothelial network. Figure 6 NESTIN staining results showed that although the NESTIN network decreased over time in all groups, statistical results at days 7 and 14 indicated that 50 μg / mL CS could promote NESTIN expression. Figure 7 ).

[0092] Simultaneously, the effects of different MS concentrations on bone marrow organoid development were investigated. The control group consisted of bone marrow organoids obtained using complete organoid culture medium without MS. Figure 8 It can be seen that the addition of MS significantly promoted the expression of CD31 and ENG on day 14. Among them, MS at a concentration of 50 μg / mL showed a more ideal effect in promoting CD31 expression. Furthermore, the expression of NESTIN showed (…). Figure 9 Both 50 μg / mL and 100 μg / mL MS groups enhanced NESTIN expression on day 7, which is crucial for maintaining HSCs and promoting bone marrow function. Overall, the addition of certain amounts of inorganic active materials CS or MS can promote the development of blood vessels and NESTIN networks in bone marrow organoids, thus optimizing organoid structure and function. 50 μg / mL CS and MS showed relatively superior effects in promoting BMO development.

[0093] Bone marrow organoids cultured in complete medium are called BMOs, while those formed in conditioned medium containing 50 μg / mL CS or MS are named BMO / CS and BMO / MSS, respectively.

[0094] Subsequently, histological staining was performed on the bone marrow organoids to assess the differentiated cell types derived from MSCs in the organoids. Figure 10 Images a and 10b show the histological staining results of three different bone marrow organoids cultured for 7 and 14 days, respectively. Hematoxylin and eosin (H&E) staining revealed that most cells grew on the periphery of the structures, with extracellular matrix components in the middle. H&E staining images from day 14 showed clearly defined luminal structures in all three groups of organoids, which may provide an ideal niche environment for HSC recruitment. Furthermore, AB and Oil Red O staining revealed chondrogenic and adipogenic differentiation of the bone marrow organoids. PAS and SR staining results indicated that the organoids contained abundant collagen and polysaccharides, such as glycosaminoglycans, which are known extracellular matrix components of MSCs residing sites in natural bone marrow. In addition, expression of the transcription factor RUNX2, which regulates osteogenic differentiation of MSCs, was detected in BMOs. Figure 10 c). RUNX2 expression was more pronounced in the BMO / MSS group, indicating that MS addition promoted osteogenic differentiation of MSCs. Figure 10 d). In summary, bone marrow organoids cultured for 7 and 14 days exhibited the extracellular matrix components of MSCs in native bone marrow, including glycogen and collagen, as well as self-renewal and differentiation characteristics, allowing partial differentiation into adipocytes, chondrocytes, and osteoblasts.

[0095] The behavioral regulation of hematopoietic stem cells by functionalized bone marrow organoids.

[0096] Based on the above analysis, the addition of CS and MSS can promote the development of bone marrow organoids and support the formation of functional bone marrow organoids. Next, the effects of different bone marrow organoids under CS or MS on HSCs were investigated. First, the effects of BMOs on CD34 were studied. + The recruitment effect of HSCs. Homegrown hematopoietic stem cells / progenitor cells (HSPCs) were monitored using CD45. Figure 11 As shown in ab, the number of HSPCs in each BMO / MSS group was significantly higher than that in the BMO and BMO / CS groups. There was no significant difference between the BMO and BMO / CS groups. CD45 homing to each organoid... + Statistical analysis of cell counts also confirmed this conclusion. A rich endothelial network facilitates the migration of HSPCs. Therefore, BMO / MSS organoids exhibited a stronger recruitment effect on HSPCs. Next, functionalized bone marrow organoids constructed under CS and MS conditions were combined with CD34... + HSCs were co-cultured to investigate the effects of BMOs on HSC division and apoptosis. Figure 11 c). To study the splitting of HSCs, HSCs were pre-labeled with CFSE. The control group consisted of HSCs labeled with CD34. +HSCs were cultured alone. The BMO, BMO / CS, and BMO / MSS groups represented different bone marrow organoids and labeled CD34, respectively. + HSCs were co-cultured. Results showed that, compared to the BMO group, the HSCs in the BMO / CS and BMO / MSS groups had higher division rates. Figure 11 c). The proportion of cell division can reflect the proliferative capacity of HSCs. Therefore, organoids formed under the influence of CS or MSS promote HSC proliferation more effectively than those in the BMO group. Maintaining HSC viability is crucial for their hematopoietic function. Therefore, the apoptosis of HSCs under the influence of functionalized bone marrow organoids was tested. The control group (Control) was prepared by adding CD34... + HSCs were cultured separately. The BMO, BMO / CS, and BMO / MSS groups represented different bone marrow organoids and CD34 groups, respectively. + HSCs were co-cultured. Figure 11 As can be seen, the presence of BMO, BMO / CS, and BMO / MSS significantly improved the survival rate of HSCs, at 63.3%, 67.1%, and 74.2%, respectively, while the survival rate of the control group without organoids was only 53.9%. Therefore, organoids formed under the influence of CS or MS can promote the division and survival of HSCs, which is beneficial to the function of HSCs. Overall, CS and MSS have a positive effect on the construction of functional bone marrow organoids, while bone marrow organoids formed under the influence of MS are superior in maintaining HSCs (see [reference]). Figure 11 ).

[0097] Ion release from CS nanowires and MS nanospheres.

[0098] Subsequently, ion release from 50 μg / mL CS and MS immersed in DMEM / F12 medium was tested. On days 1, 3, 7, and 14, the Ca ion concentration in CS was significantly higher than that in the Control group (DMEM / F12 medium) and the MSS group. There were significant differences in the release patterns of Si ions between the CS and MSS groups. Si ions in the CS group were rapidly released on day 1, while on days 3, 7, and 14, there was no significant difference in Si ion concentration between the CS group and day 1, indicating that Si ion release had stabilized by day 1. The Si ion release concentration in the MSS group showed a gradual increasing trend over time. Similarly, the Mg ion release pattern in MSS was consistent with that of Si ions. These differences in ion release patterns between CS and MSS may have different effects on bone marrow organoid development (see [link to relevant documentation]). Figure 12 ).

[0099] In vitro bioactivity of functionalized bone marrow organoids.

[0100] Organoids hold immense potential for applications in the biomedical field. However, their in vitro biological functions remain unclear. In particular, their in vitro bioactivity compared to cells warrants further investigation. Therefore, we used a mixture of MSCs and ECs, based on their proportions and quantities in forming bone marrow organoids, as a control group to explore the differences in biological effects between organoids and cells. Three different bone marrow organoids were dispersed in GelMA hydrogels, and then a co-culture system of organoids / hydrogels and important cells associated with tissue regeneration (chondrocytes, bone marrow mesenchymal stem cells) was constructed using Transwell. The hydrogels were loaded with mixtures of MSCs and ECs under different conditions as control groups. Specifically, the blank group consisted of individually cultured important cells associated with tissue regeneration; the Cells group consisted of a mixture of MSCs and ECs cultured in complete medium for 7 days loaded into the hydrogel; the Cells / CS group consisted of a mixture of MSCs and ECs cultured in CS-containing medium for 7 days loaded into the hydrogel; and the Cells / MSS group consisted of a mixture of MSCs and ECs cultured in MS-containing medium for 7 days loaded into the hydrogel. The BMO group consisted of bone marrow organoids cultured in complete medium for 7 days, loaded into hydrogels; the BMO / CS group consisted of bone marrow organoids cultured in CS-conditioned medium, loaded into hydrogels; and the BMO / MSS group consisted of bone marrow organoids cultured in MS-conditioned medium, loaded into hydrogels. First, the differentiation of rabbit chondrocytes (RCs) after 5 days of co-culture was assessed by immunofluorescence. Figure 13 As shown in figure a, the expression of Col 2 and Sox9 was relatively high in the three organoid-based RCs. Furthermore, qPCR results showed that, compared to the control group, the expression of Aggrecan and Sox9 was upregulated in the other four groups, with higher overall expression in the BMO and BMO / MSS groups. Figure 13 b). Subsequently, the osteogenic differentiation activity of rabbit bone marrow mesenchymal stem cells (rMSCs) in the co-culture system was characterized. From Figure 14 As can be seen, Col 1 and Opn expression were significantly higher in the BMO, BMO / CS, and BMO / MSS groups. Furthermore, when co-cultured with BMO / MSS, rMSCs exhibited higher osteogenic gene expression (Col 1 and Runx2), indicating the highest osteogenic differentiation activity. Figure 14 b).

[0101] Functional bone marrow organoids promote osteochondral tissue regeneration in vivo.

[0102] Given the excellent in vitro biological activity of bone marrow organoids, a rabbit osteochondral defect model was further constructed to demonstrate the performance of functionalized bone marrow organoids in tissue regeneration. Specifically, under MS (microsurgical treatment), bone marrow organoids or a mixture of MSCs and ECs cultured for 7 days were loaded into GelMA hydrogel, and then the hydrogel blocks were implanted into the osteochondral defect. After 8 weeks of repair, tissue samples were collected for biological evaluation. Analysis was performed based on Micro-CT reconstruction results. Compared with other groups, the BMO / MSS group showed more newly formed bone (green, ...) within the internal space. Figure 15 a). Furthermore, statistical analysis showed that the ratio of BV (bone volume) to TV (total volume) in the BMO / MSS group was significantly higher than that in the other four groups. Figure 15 (b) In particular, the newly formed bone in the BMO / MSS group was significantly higher than that in the BMO group, indicating that the organoids constructed under MS treatment have superior in vivo osteogenic activity. Next, all samples were decalcified, embedded, and sectioned, and the microstructure of the newly formed osteochondral tissue was assessed by histological staining. H&E staining showed that the Blank group exhibited persistent cartilage defects, with the newly formed tissue being structurally disordered fibrous tissue accompanied by some inflammatory cell infiltration. The Cells, Cells / MSS, and BMO groups still showed varying degrees of cartilage defects, while the cartilage layer in the BMO / MSS group grew well (…). Figure 16 ).

[0103] In summary, the purpose of this invention is to prepare a functionalized bone marrow organoid for the repair of osteochondral defects. The functionalized bone marrow organoid is formed under the action of inorganic bioactive materials CS or MS. The developed bone marrow organoid exhibits ideal in vitro bioactivity, including HSC behavioral regulation ability and excellent osteogenic activity. The addition of CS or MS further enhances the performance of the constructed functionalized bone marrow organoid, significantly promoting the repair of osteochondral defects in rabbits. This invention provides an innovative paradigm for using bone marrow organoids to repair skeletal system defects.

Claims

1. A functionalized bone marrow organoid, characterized in that, The functionalized bone marrow organoids are organoids with natural bone marrow structure and functional characteristics formed by the spontaneous aggregation of mesenchymal spheroids of bone marrow mesenchymal stem cells and endothelial cells loaded in an agarose microporous array and developed in a conditioned medium containing silicate bioceramics.

2. The functionalized bone marrow organoid according to claim 1, characterized in that, The endothelial cells are human umbilical vein endothelial cells.

3. The functionalized bone marrow organoid according to claim 1 or 2, characterized in that, The initial loading ratio of bone marrow mesenchymal stem cells to endothelial cells was 1:1 to 3:

1.

4. The functionalized bone marrow organoid according to any one of claims 1 to 3, characterized in that, In each well of the agarose microwell array, the total number of bone marrow mesenchymal stem cells and endothelial cells seeded is 400 to 1000.

5. The functionalized bone marrow organoid according to any one of claims 1 to 4, characterized in that, The silicate bioceramic is calcium silicate and / or magnesium silicate.

6. The functionalized bone marrow organoid according to any one of claims 1 to 5, characterized in that, The mass concentration of silicate bioceramics in the conditioned medium is not higher than 200 μg / mL, preferably 50–100 μg / mL.

7. The functionalized bone marrow organoid according to any one of claims 1 to 6, characterized in that, The agarose micropore array has an agarose mass fraction of 1.5% to 3%.

8. The method for preparing functionalized bone marrow organoids according to any one of claims 1 to 7, characterized in that, The preparation method includes: seeding bone marrow mesenchymal stem cells and endothelial cells into an agarose microwell array and culturing them until they spontaneously aggregate to form mesenchymal spheres; dispersing silicate bioceramics into organoid complete culture medium to obtain conditioned medium; subsequently changing the culture environment and replacing the medium with conditioned medium containing silicate bioceramics, and continuing to culture to construct functional bone marrow organoids.

9. The preparation method according to claim 8, characterized in that, The culture time in the conditioned medium containing silicate bioceramics is 7–14 days.

10. The use of a functionalized bone marrow organoid according to any one of claims 1 to 7 in the preparation of tissue regeneration materials.